Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. (PFE) has filed a new Phase 1 study, titled “A PHASE 1, OPEN-LABEL, 4-PERIOD, FIXED-SEQUENCE STUDY…” to track how its experimental drug PF-07328948 moves through the body of healthy adult men. The goal is to see how the drug is absorbed, spread, broken down, and cleared, which is vital before larger studies and any future commercial plans.
The study tests PF-07328948 given as oral liquid and tablet forms, plus a version tagged with a tiny radioactive tracer. The tracer helps measure how much of the drug gets into the blood and how fast the body removes it, guiding dose selection and future trial design.
This is an interventional trial with no placebo group and no blinding. All volunteers receive the active drug in different periods, so researchers can compare oral and intravenous dosing and understand basic science questions rather than direct treatment benefit.
The study is not yet recruiting, with first submission dated March 27, 2026, and the last update filed April 6, 2026. Key completion dates, including primary and final readouts, are still ahead, so investors should view this as early groundwork rather than a near-term catalyst.
For the market, this update signals Pfizer’s ongoing push to refresh its pipeline but has limited short-term impact on PFE’s share price. Competitors with deeper late-stage assets will still dominate near-term sentiment, while this early program mainly supports the long-run narrative of R&D depth at Pfizer.
The study remains in an early, non-recruiting stage, and investors can find further updated details on the ClinicalTrials portal as the program progresses.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.
